CytomX, University of Texas MD Anderson Cancer Center deal

CytomX and MD Anderson will research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies against multiple undisclosed targets using CytomX’s Probody technology. Both partn...